Yosipovitch Gil, Biazus Soares Georgia, Mahmoud Omar
Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miami Itch Center, University of Miami Miller School of Medicine, 5555 Ponce de Leon, Coral Gables, FL, 33146, USA.
Dermatol Ther (Heidelb). 2023 Aug;13(8):1647-1660. doi: 10.1007/s13555-023-00972-6. Epub 2023 Jun 29.
Chronic spontaneous urticaria (CSU) is a condition in which wheals, angioedema, and pruritus occur spontaneously and recurrently for at least 6 weeks. The etiology of this disease is partially dependent on production of autoantibodies that activate and recruit inflammatory cells. Although the wheals can resolve within 24 h, symptoms have a significant detrimental impact on the quality of life of these patients. Standard therapy for CSU includes second-generation antihistamines and omalizumab. However, many patients tend to be refractory to these therapies. Available treatments such as cyclosporine, dapsone, dupilumab, and tumor necrosis factor alpha (TNFa) inhibitors have been used with success in some cases. Furthermore, various biologics and other novel drugs have emerged as potential treatments for this condition, and many more are currently under investigation in randomized clinical trials.
慢性自发性荨麻疹（CSU）是一种风团、血管性水肿和瘙痒自发且反复出现至少6周的病症。该疾病的病因部分取决于激活和募集炎症细胞的自身抗体的产生。尽管风团可在24小时内消退，但症状对这些患者的生活质量有显著的不利影响。CSU的标准治疗包括第二代抗组胺药和奥马珠单抗。然而，许多患者往往对这些治疗无效。环孢素、氨苯砜、度普利尤单抗和肿瘤坏死因子α（TNFα）抑制剂等现有治疗方法在某些情况下已取得成功。此外，各种生物制剂和其他新药已成为该病症的潜在治疗方法，目前还有更多药物正在随机临床试验中进行研究。
